(Q37399907)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

review article

1 reference

title

Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

H Van Poppel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

B Van Cleynenbreugel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

F M Mottaghy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

R Oyen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

24 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

Prostate Cancer and Prostatic Diseases

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

116-123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Management of patients with an increasing prostate-specific antigen after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Antiandrogen treatments in locally advanced prostate cancer: are they all the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Role of androgen deprivation therapy for node-positive prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Treatment of PSA only recurrence of prostate cancer after prior local therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

EAU guidelines on prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta")

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

The potential value of power Doppler ultrasound imaging compared with grey-scale ultrasound findings in the diagnosis of local recurrence after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Role of Dynamic Contrast-Enhanced Magnetic Resonance (MR) Imaging and Proton MR Spectroscopic Imaging in the Detection of Local Recurrence after Radical Prostatectomy for Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Risk of prostate carcinoma death in patients with lymph node metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.3

31 March 2020

Identifiers

DOI

10.1038/PCAN.2009.3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238169%20AND%20SRC:MED&resulttype=core&format=json

release_rod3kjgchvepngchl6ebqmxjcu

22 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rod3kjgchvepngchl6ebqmxjcu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference